Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-919 Safety and Immunogenicity in Healthy Japanese Adults
NCT04677660Phase 2Completed
- Sponsor
- Takeda
- Start
- Jan 2021
- Primary completion
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of elasomeran in coronavirus disease 2019 (COVID-19), sponsored by Takeda. Started Jan 2021; status: completed.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04677660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04677660.